Portal de Periódicos da CAPES

Myelodysplastic syndromes: lost between two states?

2010; Springer Nature; Volume: 24; Issue: 1 Linguagem: Inglês

10.1038/leu.2009.157

1476-5551

Claire Acquaviva, Véronique Gelsi‐Boyer, Daniel Birnbaum,

Ubiquitin and proteasome pathways

Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematological diseases characterized by bone marrow hypercellularity, dysplasia, various degrees of cytopenia and a risk of progression to acute myeloid leukemia (AML). There has been little progress toward the molecular classification of MDSs and the identification of new markers and therapeutic targets. Using the International Prgonostic Scoring System, MDSs are classified as being at low, intermediate and high risk of developing AML.1, 2 New developments in the understanding of the molecular alterations and mechanisms leading to MDS could result in a better understanding of the physiology of the hematopoietic system, an accurate classification of the syndromes, a reliable evaluation of the prognosis for the patients and the design of efficient therapies. Here, we propose a speculative interpretation of the latest molecular results in the field.